It’s fairly standard for a biotech to frame a study that missed its primary endpoint as offering promise on other measures, but Savara Inc.’s attempt to depict its unsuccessful Phase III IMPALA study of Molgradex in autoimmune alveolar pulmonary proteinosis (aPAP) as a “successful failed study” is not resonating with investors.
The Austin, TX-based biotech reported after market closing on 12 June that Molgradex – an inhaled recombinant formulation of human...